Table 18.8
Myeloma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races				Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females	
5-Year Relative Survival	(Percent)									
Year of Diagnosis:				1.0	1.0	1.0				
1960-1963 ^a	- -	_	- -	12	13	10	_	_	_	
1970-1973 ^a		-		19	20	17	-	-	-	
1975-1977 ^b	25.1	24.5	25.8	24.5	24.0	25.1	30.3	31.0	29.6	
1978-1980 ^b	26.0	24.6	27.4	25.0	24.5	25.6	31.9	27.4	36.2	
1981-1983 ^b	27.8	25.9	29.7	27.5	25.7	29.3	28.9	29.8	27.9	
1984-1986 ^b	27.4	27.9	27.0	26.2	26.1	26.3	32.1	33.3	30.9	
1987-1989 ^b	27.5	29.1	25.9	27.2	29.3	25.0	30.3	30.3	30.3	
1990-1992 ^b	29.5	30.8	28.1	28.6	29.8	27.2	34.6	38.6	30.8	
1993-1995 ^b	32.0	32.4	31.6	30.9	31.6	30.2	35.6	34.8	36.0	
1996-1998 ^b	32.6	34.8	30.1	32.4	34.7	29.8	31.2	32.9	30.0	
1999-2001 ^b	34.2	36.9	31.1	34.2	37.0	30.7	33.1	35.9	30.7	
2002-2008 ^b	42.6 ^f	43.8 ^f	41.2 ^f	42.9 ^f	44.9 ^f	40.4 ^f	42.7 ^f	41.5 ^f	43.9 ^f	
5-Year Period Survival (I	Percent) ^{cd}									
2008	42.2	43.2	40.9	42.3	44.0	40.1	41.4	40.5	42.2	
Stage Distribution (%) 20	002-2008 ^{ce}									
All Stages	002 2000									
Number of cases	26,471	14,301	12,170	19,665	10,931	8,734	5,055	2,469	2,586	
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%	
Localized	5	6	4	5	6	4	4	4	3	
Regional	0	0	0	0	0	0	0	0	0	
Distant	95	94	96	95	94	96	96	96	97	
Unstaged	0	0	0	0	0	0	0	0	0	
unstaged	U	U	U	U	U	U	U	U	U	
5-Year Relative Survival	(Percent), 2	002-2008 ^c								
Age at Diagnosis:										
Ages <45	63.9	65.4	61.8	63.9	66.9	58.4	63.1	60.9	65.3	
Ages 45-54	57.2	55.5	59.6	60.2	58.6	62.7	49.0	44.6	53.6	
Ages 55-64	50.8	50.2	51.6	51.2	50.6	52.0	48.6	46.3	51.2	
Ages 65-74	39.0	38.2	39.9	39.1	38.9	39.5	36.8	35.2	38.5	
Ages 75+	24.5	25.8	23.4	24.5	26.7	22.5	23.6	21.1	25.1	
Ages <65	54.4	53.6	55.4	55.4	55.0	56.1	50.7	47.4	54.1	
Ages 65+	31.3	32.2	30.4	31.2	32.8	29.4	30.7	29.6	31.6	
Stage ^e :										
All Stages	41.1	42.1	40.1	40.9	42.6	38.8	41.0	39.5	42.4	
Localized	67.0	71.6	59.4	67.1	72.3	57.8	58.1	59.7 ^g	55.8 ^g	
Regional	-	7 = . 0	-	-	, 2.5	-	-	-	-	
	39.8	40.3	39.3	39.4	40.6	38.0	40.3	38.6	41.9	
Distant				19.4				3 N . P		

Based on End Results data from a series of hospital registries and one population-based registry.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2009.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2009.

Period survival provides a 2008 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2006-2008: 0-1 year survival), (2004-2006: 2-3 year survival), (2003-2005: 3-4 year survival), (2002-2004: 4-5 years survival). Stage at diagnosis is classified using SEER Summary Stage 2000.

The difference between 1975-1977 and 2002-2008 is statistically significant (p<.05).

The difference between 1975-1977 and 2002-2006 is statistically significant (pt.

The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

Statistic could not be calculated due to fewer than 25 cases during the time period.